Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: Antitumor activity comparing with that induced by autologous vaccine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 6, 2007, Pages 790-798

  Li, Hui ^a   Jiang, Hong Jing ^a   Ma, Ming Quan ^a   Wei, Feng ^a   An, Xiu Mei ^a   Ren, Xiu Bao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic vaccine; Autologous vaccine; Immune responses; Lung cancer; Mouse model

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 4; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SPLEEN CELL; STATISTICAL SIGNIFICANCE; SURVIVAL; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON TYPE II; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 37549013307     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.360     Document Type: Article

References (15)

1. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539.
2. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviralmediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343.
3. Kusumoto M, Umeda S, Ikubo A, et al. Phase I clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 2001;50:373.
4. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160.
5. Kenzaburo Tani, Miyuki Azuma, Yukoh Nakazaki, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol Ther 2004;10(4):799.
6. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. Natl Cancer Inst 2004;96:326.
7. Hrouda D, Todryk SM, Perry MJA, et al. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 2000;86:742.
8. The Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised, clinical trials. BMJ 1995;311:899.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2003;346:92.
10. Sette A, Keogh E, Ishioka G, et al. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Invest Drugs 2002;3(1):132.
11. Dranoff, G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147.
12. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev 2002;13:185.
13. Couch M, Saunders JK, O'Malley BW, Jr, et al. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope 2003;113:552.
14. J Nemunaitis, T Jahan, H Ross, et al. Phase I/II trial of autologous tumor mixed with an allogeneic GVAXs vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13:555.
15. Yamada A, Kawano K, Koga, M., et al. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T-lymphocytes. Cancer Res 2003;63:2829.